rs752950007
Variant summary
Our verdict is Benign. Variant got -11 ACMG points: 0P and 11B. BP4_ModerateBP6_Very_StrongBP7
The NM_000535.7(PMS2):c.2049C>T(p.Asn683Asn) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000366 in 1,584,426 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_000535.7 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -11 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000396 AC: 6AN: 151484Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000707 AC: 15AN: 212056Hom.: 0 AF XY: 0.000104 AC XY: 12AN XY: 115824
GnomAD4 exome AF: 0.0000363 AC: 52AN: 1432942Hom.: 0 Cov.: 28 AF XY: 0.0000393 AC XY: 28AN XY: 711756
GnomAD4 genome AF: 0.0000396 AC: 6AN: 151484Hom.: 0 Cov.: 31 AF XY: 0.0000270 AC XY: 2AN XY: 73978
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Benign:4
- -
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
The synonymous variant NM_001322014.2(PMS2):c.2049C>T (p.Asn683=) has not been reported previously as a pathogenic variant, to our knowledge. The p.Asn683= variant is not predicted to disrupt an existing splice site. For these reasons, this variant has been classified as Likely Benign. -
- -
not specified Benign:2
Variant summary: PMS2 c.2049C>T alters a conserved nucleotide resulting in a synonymous change. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 6.3e-05 in 239440 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in PMS2 causing Lynch Syndrome (6.3e-05 vs 0.00011), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.2049C>T in individuals affected with Lynch Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. One laboratory in ClinVar has classified the variant as likely benign in 2014. Based upon our independent evaluation, no additional evidence supporting a pathogenic outcome have emerged between 2014 to present. Based on the evidence outlined above, the variant was classified as likely benign. -
- -
not provided Benign:1
- -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Malignant tumor of breast Benign:1
The PMS2 p.Asn683=variant was not identified in the literature nor was it identified in the Cosmic, MutDB, Insight Colon Cancer Gene Variant, Zhejiang Colon Cancer, Mismatch Repair Genes Variant, and Insight Hereditary Tumors databases. The variant was identified the dbSNP (rs752950007) as “with Likely benign, uncertain significance allele”. The variant was also identified in ClinVar and in Clinvitae databases as likely benign by Ambry Genetics. The variant was identified in control databases in 15 of 239440 chromosomes at a frequency of 0.00006 increasing the likelihood that this may be a low frequency benign variant in certain populations of origin (Genome Aggregation Consortium Feb 27, 2017). The p.Asn683=variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. In addition, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at